Log in

512 Grand Pharmaceutical Group Limited HKEX · Hong Kong

Grand Pharmaceutical Group (512) news

Grand Pharmaceutical Group Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 512, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Grand Pharmaceutical Group news

We have not published a story on Grand Pharmaceutical Group yet. When there is news, it will appear here.

Questions about Grand Pharmaceutical Group

What is the ticker symbol of Grand Pharmaceutical Group?

Grand Pharmaceutical Group Limited trades under the ticker 512 on HKEX.

Where is Grand Pharmaceutical Group listed?

Grand Pharmaceutical Group Limited is listed on HKEX. Our directory also records these other listings: GETTEX:MX6A.

Which country or territory is Grand Pharmaceutical Group listed under?

Our directory records Grand Pharmaceutical Group Limited under Hong Kong.

What does Grand Pharmaceutical Group do?

Our directory classifies Grand Pharmaceutical Group Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Grand Pharmaceutical Group?

The ISIN recorded for Grand Pharmaceutical Group Limited is BMG210A71016.

Does aibio.space cover Grand Pharmaceutical Group?

aibio.space lists Grand Pharmaceutical Group Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Grand Pharmaceutical Group?

Companies in our directory listed in the same country and business area as Grand Pharmaceutical Group: Pak Fah Yeow International, Regencell Bioscience Holdings, Shenzhen Neptunus Interlong Bio-Technique Co., Sanai Health Industry Group Company, HUTCHMED (China), SSY Group.

Investor discussion: Grand Pharmaceutical Group

Members talk about Grand Pharmaceutical Group (512). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Grand Pharmaceutical Group, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: (1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR SERVING MORE THAN NINE YEARS; (3) PROPOSED ADOPTION OF NEW BYE-LAWS; AND (4) NOTICE OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: (1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS; AND (3) NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Grand Pharmaceutical Group's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    PROPOSED CHANGE OF AUDITORS

  2. HKEXnews

    Notification Letter and Reply Form to Non-registered Shareholders - Notice of publication of Interim Report

  3. HKEXnews

    Notification Letter and Reply Form to Registered Shareholders - Notice of publication of Interim Report

  4. HKEXnews

    2026 INTERIM RESULTS ANNOUNCEMENT

  5. HKEXnews

    VOLUNTARY ANNOUNCEMENT: THE GROUP'S INDEPENDENTLY DEVELOPED, BLOCKBUSTER, GLOBALLY INNOVATIVE RADIONUCLIDE-DRUG CONJUGATE, GPN01530-2, GRANTED FAST TRACK DESIGNATION BY THE FDA

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT: THE FIRST PATIENT IS ENROLLED AND DOSED IN THE PHASE III CLINICAL TRIAL OF THE GROUP'S CLASS 1.1 INNOVATIVE TRADITIONAL CHINESE MEDICINE GPN01360 CONDUCTED IN CHINA

  7. HKEXnews

    Continuing Connected Transaction

  8. HKEXnews

    BYE-LAWS

  9. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 5 JUNE 2026

  10. HKEXnews

    PROPOSED ADOPTION OF NEW BYE-LAWS

  11. HKEXnews

    Notice of Annual General Meeting

  12. HKEXnews

    (1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR SERVING MORE THAN NINE YEARS; (3) PROPOSED ADOPTION OF NEW BYE-LAWS; AND (4) NOTICE OF ANNUAL GENERAL MEETING

  13. HKEXnews

    Notice of availability to Non-registered Shareholders and Reply Form

  14. HKEXnews

    Notice of availability to Registered Shareholders and Reply Form

  15. HKEXnews

    VOLUNTARY ANNOUNCEMENT: THE CLINICAL STUDY FOR THE TREATMENT OF HCC CONDUCTED IN THE UNITED STATES OF THE GROUP'S GLOBALLY INNOVATIVE RADIOACTIVE PRODUCT SIR-SPHERES Y-90 MICROSPHERE INJECTION HAS REACHED ITS CLINICAL ENDPOINT

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT: THE GROUP ESTABLISHES A STRATEGIC PARTNERSHIP WITH THE UNIVERSITY OF HONG KONG

  17. HKEXnews

    FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025

  18. HKEXnews

    RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT: THE GROUP'S CLASS 1 INNOVATIVE TRADITIONAL CHINESE MEDICINE GPN01020 IS APPROVED TO CONDUCT PHASE II CLINICAL TRIAL IN CHINA

  20. HKEXnews

    VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATIVE PRODUCT TP-03 FOR THE TREATMENT OF DEMODEX BLEPHARITIS IS APPROVED FOR COMMERCIALIZATION IN CHINA

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:512 on TradingView.

Listing details

Grand Pharmaceutical Group Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 512, recorded under Hong Kong. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Grand Pharmaceutical Group Limited
Ticker
512
Listing
HKEX
Country or territory
Hong Kong
Business scope
Pharmaceuticals: Major
ISIN
BMG210A71016
Other listed symbols
GETTEX:MX6A
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.